February 10, 2021 -- The U.S. Patent and Trademark Office has granted a patent to Bio-Path Holdings for its nucleic acid drug platform, expanding protections for the company's DNAbilize technology.
Bio-Path was awarded U.S. patent No. 10,898,506 titled, "P-ethoxy nucleic acids for liposomal formulation."
On February 23, the company expects to be issued U.S. patent No. 10,927,379 for its lead product candidate prexigebersen, a liposomal formulation containing the antisense oligodeoxynucleotide targeting growth factor receptor-bound protein 2 (Grb2).
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
